Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
forgot about the Phentermine sales.....that could be the game changer..
I'm at 150,000 an .086 average.
I think that there will still be some remaining Lodrane 24 revenue in there along with the initial Lodrane D revenue.
What I think will happen is the 10Q will come out, not look so great and the price dips into the 8 to 8.5 range but that the CC will reveal some good news (FDA approval? Patents?) and bounces into the 10+ range. One can hope.
Very possible. Just might make for cheaper shares.
Not a loss if you don't sell. I'll hang around and see what happens. These pennies have their share of drama!
SHARE ! (please)
Means they will probably publish numbers day before no?
Thanks. May I ask where you got that? Just want to add to my resource bucket.
Bedford Report with a "research report" on ELTP out today.
Pretty light stuff but here is link to it for what its worth:
https://docs.google.com/open?id=0BwI9WYgqHk9mYzgwNGY3ZjctYjQwMC00NmUzLWIzMGItNWQxZmY0ZjI2Nzk4
http://www.marketwire.com/press-release/drug-candidates-from-rexahn-and-elite-pharmaceuticals-look-to-pass-key-tests-nyse-amex-rnn-1584417.htm
SOURCE: The Bedford Report
November 09, 2011 08:16 ET
Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests
The Bedford Report Provides Equity Research on Rexahn Pharmaceuticals & Elite Pharmaceuticals
NEW YORK, NY--(Marketwire - Nov 9, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly disappointing earnings elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the healthcare sector and provides investment research on Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) and Elite Pharmaceuticals, Inc. (OTCBB: ELTP). Access to the full company reports can be found at:
www.bedfordreport.com/RNN
www.bedfordreport.com/ELTP
Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.
Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.
The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using technology. Earlier this Fall, Elite Pharmaceuticals and ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal (Hi-Tech), announced the launch of Lodrane D®. Lodrane D® is an immediate release formulation of brompheniramine maleate and pseudoephedrine HCl, an effective, low-sedating antihistamine combined with a decongestant.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer
Did you check with the TA or did you determine this by other means?
Would love to learn your DD methods! Seriously!
http://www.wikinvest.com/stock/Dussault_Apparel_(DUSS)/Filing/8-K/2011/F94080688
Item 1.01 Entry into Material Definitive Agreement
Item 2.01 Completion of Acquisition of Assets
On April 9, 2010 our company entered into an Asset Acquisition Agreement with Open Sundaes Ventures Ltd. (“Open Sundaes”) for the acquisition of certain assets relating to the business of the production and development of beauty and bath products including inventory, intellectual property and business knowhow. In consideration for the acquisition of these assets, our company paid $60,000 and agreed to issue an aggregate of 4,000,002 shares of its common stock to the shareholders of Open Sundaes. The issuance of the common stock was done without a prospectus in reliance on exemptions under Regulation S of the Securities Act of 1933, as amended. The Asset Acquisition Agreement was approved by the shareholders of Open Sundaes at a special meeting held on April 22, 2010.
Item 3.02 Unregistered Sales of Equity Securities
Of the 4,000,002 shares of our common stock to be issued under the Asset Acquisition Agreement, we issued an aggregate of 1,026,841 shares of our common stock on December 14, 2010 to eleven (11) non-U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933), relying upon Regulation S of the Securities Act of 1933. The remaining shares under the agreement have not yet been issued and their issuance will be disclosed under a separate Form 8-K, as the remaining Open Sundaes shareholders provide certain required information.
Item 9.01 Financial Statements and Exhibits.
10.1 Asset Acquisition Agreement with Open Sundaes Ventures Ltd., dated April 9, 2010.
That's the right movie.
Don't think you have the right movie...
$800 in stock moved today. Really doesn't mean a damn thing one way or another. Until earnings or news none of these low volume days means a thing. There won't be interest and volume without earnings and/or news.
10/951,978 Extended release formulations of opioids and method of use thereof
Wow. Might be good for the stock but that is one messed up individual.
http://www.tmz.com/2007/10/06/dmx-animal-cruelty-report-results/#.Trf0evR7_xR
Being pumped..
PSP Free Members,
I hope you are enjoying this post Halloween weekend. I'm really ecstatic about this next stock and I want to make 2 things very clear for all of my subscribers.
1. I am only good to you based on the stock ideas that I bring to the table. It doesn't mean a thing if my members don't have an opportunity for massive profit potential. This means that I work hard at finding companies in hot sectors with big gain opportunities.
2. There are only a few stock plays every year that can provide win after win, no matter how many times they are traded. This is why I never shy away from covering a previous stock pick that I believe is poised yet again for potential gains.
This brings me back to SAPX! The gains offered by this "stock gem" have been quite impressive, and I expect another big run could be in play starting this week!
As you'll recall, I covered SAPX when it was trading around $0.42 cents, and last Monday it shot up to $0.675 cents, which is an astounding 62% gain! Even more impressive, is that SAPX ran up from around $1 to $5.75 this past July.
That is the kind of profit opportunity that has caused me to keep a close watch on SAPX more than any other stock I've covered all year. And guess what? I think we're just getting started!
Whether you have already taken a look at SAPX, perhaps traded the stock already, consider that at a price point back to $0.42 cents (in after-hours trading Friday), I believe SAPX is back at the starting blocks and ready to take off once again! In my view, it's a brand new opportunity based on multiple factors.
You should definitely take a look at the information posted below as it provides a great resource for your own SAPX research tonight and tomorrow morning.
-James
Seems they are very close.
New info on another patent..12/478,952....seems they stumbled across a similar foreign patent?
11-03-2011 IDS Information Disclosure Statement (IDS) Form (SB08) PROSECUTION 1
11-03-2011 TRAN.LET Transmittal Letter PROSECUTION 3
11-03-2011 FOR Foreign Reference PROSECUTION 75
11-03-2011 WFEE Fee Worksheet (SB06) PROSECUTION 2
11-03-2011 N417 EFS Acknowledgment Receipt PROSECUTION 2
Download the Zacks report here (It's on me!):
https://docs.google.com/open?id=0BwI9WYgqHk9mNGNiNzhkZjMtOTNjOC00NWE3LWJiZWYtN2M0NzhkNTlkNzk3
Yesterday:
Date......Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20111101..DUSS.....197,861..........0......................933,806........O
http://www.napp.org/disclosure/linked_files/Examiner%20Interviews.pdf
Sounds like a chance to "clear the air" a bit and get the momentum going on this app...
Can SAPX films be seen via:
Netflix/Blockbuster/Hulu/iTunes/ePix/Crackle/Amazon ??
What other distribution opportunities can they exploit?
and if you were not a complete a** you would have credited the OP with the fact that they said:
Yes, imagine something will come out formally from Elite or at least from ECR today. Nothing yet: http://www.ecrpharma.com/newsline/index.html
The point was to give the link to LOOK OUT FOR a PR....
Give it up already OK?
They were hired to form a committee to make recommendations.
I guess their work is now done.
Jason Dussault, President and CEO of Dussault Apparel, commented, "I am happy to announce the appointment of Ms. Kim and Ms. Kostakou to our Board. The Company is facing significant challenges; the current year's lackluster revenue, recent changes of policy of the Pension Financial Services regarding the clearing of stocks priced below $0.10 and the new XBRL financial reporting requirement are hurdles the Company must overcome. It is the intent of the Company to form a committee to undertake a comprehensive review evaluating the current business of the Company to determine its viability and the Company's direction. This review is intended to include current operations of the Company, including a review of assets and liabilities, the business operations of the Company, and its trademarks with a view to providing the officers, directors and management of the Company with a report and recommendations. Ms. Kostakou and Ms. Kim will head the committee which will undertake this review, and will be responsible to gather all information from legal, consultants and management and prepare a report with recommendations to the Company. I believe it is in the best interests of the Company and its shareholders The Company may also review new financing opportunities and possible acquisitions to enhance its asset value."
Read more: www.andhranews.net/Business/2011/Dussault-Apparel-Inc-Appoints-Two-New-34251.htm#ixzz1cOFsmTbG
So they joined the board on 6/22 and resigned 5 months later?
http://www.andhranews.net/Business/2011/Dussault-Apparel-Inc-Appoints-Two-New-34251.htm
Yahoo has it as 11/14
Last year they announced 11/15
I am on the bus. Took a small stake yesterday at .0042
Seems like a great story and it's nice to invest in something where you have actual people to root for.
I have no choice
Bought in on the P&D at .0125 and couldn't get out fast enough.
Not a huge stake mind you but the potential is there so I may as well hang on!
-35%
Some action...
That was me selling 40,000 at .055. Had that order in for 17 days.
Just wanted see how it traded.
Wow! Great Job!
OK. That was an interesting exercise I guess!
Looks like Elite owes them some homework...
As good a guess as any!
You don't seem to see all of the back and forth that you see on the USPTO site.
PRS 121 = THE EPO HAS BEEN INFORMED BY WIPO THAT EP WAS DESIGNATED IN THIS APPLICATION''
whatever that means!